Leerink Partnrs Has Negative Estimate for TSBX Q1 Earnings

Turnstone Biologics Corp. (NASDAQ:TSBX) – Equities research analysts at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for Turnstone Biologics in a note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($0.26) for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.51) EPS.

Turnstone Biologics (NASDAQ:TSBX) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.13.

Separately, Piper Sandler lowered shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $3.75 to $0.40 in a report on Wednesday, February 5th.

Turnstone Biologics Stock Up 1.0 %

Shares of NASDAQ TSBX opened at $0.38 on Thursday. The firm has a market cap of $8.78 million, a PE ratio of -0.12 and a beta of 2.04. The company’s fifty day simple moving average is $0.41 and its 200 day simple moving average is $0.47. Turnstone Biologics has a 12-month low of $0.34 and a 12-month high of $3.88.

Institutional Investors Weigh In On Turnstone Biologics

A hedge fund recently raised its stake in Turnstone Biologics stock. FMR LLC raised its holdings in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) by 3.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,172,987 shares of the company’s stock after purchasing an additional 37,738 shares during the quarter. FMR LLC owned 5.07% of Turnstone Biologics worth $653,000 as of its most recent SEC filing. Institutional investors and hedge funds own 52.51% of the company’s stock.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.